Advertisement

Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed/refractory acute myeloid leukemia

Harry P. Erba, Pamela S. Becker, Paul J. Shami, Michael R. Grunwald, Donna L. Flesher, Min Zhu, Erik Rasmussen, Haby A. Henary, Abraham A. Anderson and Eunice S. Wang

Article Information

Citation 
vol. 3 no. 13 1939-1949
PubMed 

Print ISSN 
Online ISSN 
History 
  • Submitted January 11, 2019
  • Accepted May 10, 2019
  • Published online June 28, 2019.


Contributors 
  • Harry P. Erba, 1Division of Hematologic Malignancies and Cellular Therapy, Department of Internal Medicine, Duke University, Durham, NC;
  • Pamela S. Becker, 2Division of Hematology, University of Washington School of Medicine, Seattle, WA;3Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;
  • Paul J. Shami, 4Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT;
  • Michael R. Grunwald, 5Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC;
  • Donna L. Flesher, 6Amgen Inc., Thousand Oaks, CA; and
  • Min Zhu, 6Amgen Inc., Thousand Oaks, CA; and
  • Erik Rasmussen, 6Amgen Inc., Thousand Oaks, CA; and
  • Haby A. Henary, 6Amgen Inc., Thousand Oaks, CA; and
  • Abraham A. Anderson, 6Amgen Inc., Thousand Oaks, CA; and
  • Eunice S. Wang, 7Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY

Altmetric.com Statistics

The Altmetric score is a weighted count of online attention designed to reflect the volume and reach of online engagement surrounding an individual research output